Inostics
NEW YORK (GenomeWeb) — In a deal signed ceremoniously at the American Society of Clinical Oncology meeting earlier this week in Chicago, Merck and Sysmex Inostics will collaborate to develop and commercialize a kit to assay RAS mutations in circulating tumor DNA.
When Japan's Sysmex disclosed two weeks ago that it had acquired molecular diagnostics services firm Inostics and flow cytometry specialist Partec, it noted that the purchases were designed to aid its foray into personalized medicine and companion diagnostics.
Japanese in vitro diagnostics firm Sysmex said this week that it has acquired a pair of German companies — molecular diagnostics services firm Inostics and flow cytometry specialist Partec — in a bid to bolster its personalized medicine and companion diagnostics development business.
UPDATE: Japan's Sysmex Acquires Germany's Inostics, Partec
This story has been updated from a previous version to incorporate information about Sysmex's acquisition of Partec.
Dx Focus: Inostics OncoBEAM Blood Test; Abbott RealTime HPV Test; BioMérieux THxID BRAF assay
Premium
Inostics said this week that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBEAM tumor mutation test.